SOURCE: GelStat Corporation

December 21, 2006 11:51 ET

GelStat Announces Agreement With Leading Catalog Marketing Company

ST. PAUL, MN -- (MARKET WIRE) -- December 21, 2006 -- GelStat Corporation (PINKSHEETS: GSAC), a consumer healthcare company primarily focused on the development and marketing of over-the-counter (OTC) products for the safe and effective treatment of pain and inflammation, is pleased to announce that it has signed an agreement with Catalog Solutions, the oldest commissioned sales rep agency specializing in placing products in mail order catalogs.

John Galayda, Managing Director of GelStat's business development team U.S. Marketing, stated, "This is another significant achievement for the Company, and provides another sales channel for GelStat products that requires minimal marketing expense by GelStat. I have worked with Catalog Solutions for many years, and believe they are an ideal partner to expand our presence in American households. This new effort is expected to place GelStat products into catalogs that reach millions of consumers with virtually no up-front cost to GelStat, representing new market penetration, increased consumer awareness, and additional revenues for the Company."


Catalog Solutions, Inc. is the oldest commissioned sales rep agency specializing in the matching of products with mail order catalogs. Catalog Solutions continually updates its list of over 3,200 active mail order catalogs and has developed a special working relationship over the past 26 years with over 450 of the better-known mail catalogers. The company has a seasoned staff of catalog marketers who work to identify target customers and effectively place products into the mail order catalogs that provide the best opportunity to sell a specific product. Catalog Solutions also specializes in the "Top 70 Health, Beauty and Vitamin" and the "Top 100 Gift and Gadget" mail order catalogs. For more about Catalog Solutions visit:


GelStat Corporation is dedicated to providing safe and effective over-the-counter (OTC) treatments for pain and inflammation. GelStat's first product, GelStat Migraine, is sold nationwide through retail chain stores, independent retailers and pharmacies, and direct to consumer channels. GelStat Migraine is a sublingually (under the tongue) administered OTC medication for acute relief from the pain and associated symptoms of migraine. Over 90 percent of the 30 million Americans with migraine use OTC headache remedies, generally aspirin or other non-steroidal anti-inflammatory drugs. Americans spend $2.6 billion each year on 600 million units of such products, although they are believed to be effective for only about 25 percent of those with moderate to severe migraine.

Click the following links to view supporting information on the effectiveness of GelStat Migraine:

Initial Clinical Trial of GelStat Migraine Shows it to be Effective for 83 Percent of those with Moderate to Severe Migraine

GelStat is Effective in Relieving Migraine Pain in a Double-Blind, Placebo-Controlled study

2 Minute Video Demonstrating the Product and its Successful Treatment of a Migraine Headache

The Company also has a suite of additional, effective healthcare products that address large consumer markets. GelStat™ Arthritis is the second available product to utilize GelStat's patent-pending formulation and is provided as a daily use, sublingual dissolving tablet. The Center for Disease Control estimates that, in its many forms, arthritis affects up to 70 million Americans. The Company has also developed "GelStat™ Sinus" and "GelStat™ Sleep," and believes that each of these products performs well and is effective for its intended use. The National Institute of Allergy and Infectious Disease estimates that 37 million Americans are affected by sinusitis every year, with at least 20 million more suffering from allergies. Approximately 70 million Americans are reported to be "problem sleepers."

For more information, visit

Safe Harbor Statement Under the Private Securities Litigation Act of 1995

With the exception of historical information, the matters discussed in this press release are forward-looking statements that involve a number of risks and uncertainties. The actual future results of GelStat could differ significantly from those statements. Factors that could cause actual results to differ materially include risks and uncertainties such as the inability to finance the company's operations or expansion, inability to hire and retain qualified personnel, changes in the general economic climate, including rising interest rate and unanticipated events such as terrorist activities. In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," or "continue," the negative of such terms, or other comparable terminology. These statements are only predictions. Although we believe that the expectations reflected in the forward-looking statements are reasonable, such statements should not be regarded as a representation by the Company, or any other person, that such forward-looking statements will be achieved. We undertake no duty to update any of the forward-looking statements, whether as a result of new information, future events or otherwise. In light of the foregoing, readers are cautioned not to place undue reliance on such forward-looking statements. For further risk factors, please review our SEC filings.

Contact Information